Sustained-release Madopar HBS® compared with standard Madopar® in the long-term treatment of de novo parkinsonian patients

Acta Neurologica Scandinavica

Volumn 93, Issue 1, 1996, Pages 14-20

  Dupont, E ^a   Andersen, A ^b   Boas, J ^c   Boisen, E ^d   Borgmann, R ^e   Helgetveit, A C ^f   Kjaer M O ^g   Kristensen, T N ^h   Mikkelsen, B ⁱ   Pakkenberg, H ^j   Presthus, J ^f   Stien, R ^f   Worm Petersen, J ^k   Buch, D ⁱ  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b TELEMARK HOSPITAL   (Norway)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^d Sønderborg Hospital   (Denmark)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^f Department of Preventive Medicine   (Norway)

^g HOLSTEBRO HOSPITAL   (Denmark)

^h AALBORG UNIVERSITY HOSPITAL   (Denmark)

ⁱ Pharma Marketing   (Denmark)

^j HVIDOVRE HOSPITAL   (Denmark)

^k GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

more..

Author keywords

Controlled long term treatment; Early Parkinson's disease; Madopar HBS; Sustained release levodopa

Indexed keywords

BENSERAZIDE; BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; LEVODOPA; SELEGILINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 9044245701     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1996.tb00163.x     Document Type: Article

References (30)

1. MARSDEN CD, PARKES JD. On-off effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976: i: 292-296.
2. CHASE TN, MOURADIAN MM, ENGBER TM. Motor response complications and the function of striatal efferent systems. Neurology 1993: 43(suppl 6): S23-S27.
3. POEWE W. Clinical and pathophysiologic aspects of late levodopa failure. Neurology 1993: 43(suppl 6): S28-S30.
4. HARDIE JR, LEES AJ, STERN GM. On-off fluctuations in Parkinson's disease: a clinical and neuropharmacological study. Brain 1984: 107: 487-506.
5. QUINN NP, PARKES JD, MARSDEN CD. Control of on-off phenomena by continuous intravenous infusion of levodopa. Neurology 1984: 34: 1131-1136.
6. NUTT JG. On-off phenomenon: Relation to levodopa pharmacokinetics and pharmacodynamics. Ann Neurol 1987: 22: 535-540.
7. ERNI W, HELD K. The hydrodynamically balanced system: a novel principle of controlled drug release. Eur Neurol 1987: 27 (suppl 1): 21-27.
8. CEDERBAUM JM, BRECK L, KUTT H et al. Controlled release levodopa/carbidopa. II. Sinemet CR-4 treatment of response fluctuations in Parkinson's disease. Neurology 1987: 37: 1607-1612.
9. DA PRADA M, KETTLER R, ZÜRCHER G, SCHAFFNER R, HAEFELY WE, Inhibition of decarboxylase and levels of dopa and 3-O-rnethyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in Volunteers. Eur Neurol 1987: 27(suppl 1): 9-20.
10. MARSDEN CD, RINNE UK, KOELLA WP, DUBUIS R, ed. International workshop on the "on-off"-phenomenon in Parkinson's disease. Eur Neurol 1987: 27(suppl 1): 1-138.
11. POEVE WH, LEES AJ, STERN GM. Treatment of motor fluctuations in Parkinson's disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations: Clin Neuropharmacol 1986: 9: 430-439.
12. HOEHN MM, YAHR MD. Parkinsonism: onset, progression and mortality. Neurology 1967: 17: 427-442.
13. WEBSTER DD. Clinical analysis of the disability in Parkinson's disease. Modern Treatment 1968: 5: 257-282.
14. CANTER CJ, DE LA TORRE R, MIER M. A method of evaluating disability in patients with Parkinson's disease. J Nerv Ment Dis 1961: 133: 143-147.
15. FAHN S, ELTON RL and members of The UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: FAHN S, MARSDEN CD, CALNE D, GOLDSTEIN M, ed. Recent developments in Parkinson's disease, vol II. Florham Park, NJ: Macmillan Healthcare Inform, 1987: 153-163 and 293-304.
16. DUVOISIN RC, ed. New strategies in dopaminergic therapy of Parkinson's disease: the use of controlled release formulation. Neurology 1989: 39(suppl 2): 1-106.
17. LEWITT PA, NELSON MV, BERCHOU RC et al. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR-4) clinical and pharmaco-kinetic studies. Neurology 1989: 39(suppl 2): 45-53.
18. GRAHNÉN A, ECKERNÄS S-Å, COLLIN C, LING-ANDERSSON A, TIGER G, NILSSON M. Comparative multidose pharmacokinetics of controlled-release levodopa products. Eur Neurol 1992: 32: 34-38.
19. CLAVERIA LE, CALNE DB, ALLEN JG. On-off phenomena related to high plasma levodopa. Br Med J 1973: ii: 641-643.
20. KOLLER WC, ed. Role of the controlled-release formulation of carbidopa-levodopa in the treatment of Parkinson's disease. Neurology 1992: 42(suppl 1): 1-60.
21. AGNOLI A, CAMPANELLA G ed. New developments in therapy of Parkinson's disease. Proceedings. Rome: JOHN LIBBEY CIC s.r.l. 1990: 1-53.
22. KLEEDORFER B, POEWE W. Comparative efficacy of two oral sustained-release preparations of L-dopa in fluctuating Parkinson's disease. Preliminary findings in 20 patients. J Neural Transm (P-D Sect) 1992: 4: 173-178.
23. RINNE UK, RINNE JO. Treatment of early Parkinson's disease with controlled-release levodopa preparations. Neurology 1989: 39(suppl 2): 78-81.
24. OLANOW CW, NAKANO K, NAUSIEDA P et al. An open multicenter trial of Sinemet CR in levodopa-naive Parkinson's disease patients. Clin Neuropharmacol 1991: 14: 3: 235-240.
25. RINNE UK, RINNE JO. Madopar HBS in the treatment of early Parkinson's disease. In: AGNOLI A, CAMPANELLA C, ed. New developments in therapy of Parkinson's disease. Rome: John Libbey CIC s.r.l., 1991: 17-21.
26. MARION MH, STOCCHI F, QUINN NP, JENNER P, MARSDEN CD. Single-dose study of slow release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease. In: YAHR, BERGMANN, ed. Advances in neurology. New York: Raven Press, 1986: 45: 493-496.
27. CHASE TN, MOURADIAN MM, ENGBER TM. Motor response complications and the function of striatal efferent systems. Neurology 1993: 43(suppl 6): S23-S27.
28. LARSEN JP, DUPONT E, TANDBERG E. Clinical diagnosis of Parkinson's disease. Proposal of diagnostic subgroups classified at different levels of confidence. Acta Neurol Scand 1994: 89: 242-251.
29. QUINN NP. Multiple system atrophy - the nature of the beast. J Neurol Neurosurg Psychiatry 1989 (suppl): 78-89.
30. QUINN NP, MARSDEN CD. The motor disorder of multiple system atrophy. J Neurol Neurosurg Psychiatry 1993: 56: 1239-1242.